Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Su Qiu

Showing results (51-60 of 62) with videos related to

Pageof 7
Sort By:
Journal of Medicinal Chemistry|March 24, 2007
Pyrogallol-based molecules as potent inhibitors of the antiapoptotic Bcl-2 proteinsGuozhi Tang, Chao-Yie Yang, Zaneta Nikolovska-Coleska, et al.
Cancer Research|November 18, 2008
SM-164: a novel, bivalent Smac mimetic that induces apoptosis and tumor regression by concurrent removal of the blockade of cIAP-1/2 and XIAPJianfeng Lu, Longchuan Bai, Haiying Sun, et al.
Journal of the American Chemical Society|July 21, 2005
Structure-based design of potent non-peptide MDM2 inhibitorsKe Ding, Yipin Lu, Zaneta Nikolovska-Coleska, et al.
Molecular Cancer Therapeutics|June 21, 2008
Reactivation of p53 by a specific MDM2 antagonist (MI-43) leads to p21-mediated cell cycle arrest and selective cell death in colon cancerSanjeev Shangary, Ke Ding, Su Qiu, et al.
Journal of the American Chemical Society|November 15, 2007
Design, synthesis, and characterization of a potent, nonpeptide, cell-permeable, bivalent Smac mimetic that concurrently targets both the BIR2 and BIR3 domains in XIAPHaiying Sun, Zaneta Nikolovska-Coleska, Jianfeng Lu, et al.
Molecular Cancer Therapeutics|March 5, 2011
Therapeutic potential and molecular mechanism of a novel, potent, nonpeptide, Smac mimetic SM-164 in combination with TRAIL for cancer treatmentJianfeng Lu, Donna McEachern, Haiying Sun, et al.
Nature Immunology|June 11, 2003
An essential role for NOD1 in host recognition of bacterial peptidoglycan containing diaminopimelic acidMathias Chamaillard, Masahito Hashimoto, Yasuo Horie, et al.
Journal of Medicinal Chemistry|June 8, 2007
Structure-based design of flavonoid compounds as a new class of small-molecule inhibitors of the anti-apoptotic Bcl-2 proteinsGuozhi Tang, Ke Ding, Zaneta Nikolovska-Coleska, et al.
The Journal of Experimental Medicine|January 19, 2006
Nod1 acts as an intracellular receptor to stimulate chemokine production and neutrophil recruitment in vivoJunya Masumoto, Kangkang Yang, Sooryanarayana Varambally, et al.
Journal of Medicinal Chemistry|March 30, 2011
A potent and orally active antagonist (SM-406/AT-406) of multiple inhibitor of apoptosis proteins (IAPs) in clinical development for cancer treatmentQian Cai, Haiying Sun, Yuefeng Peng, et al.
Pageof 7

Showing results (51-60 of 62) with videos related to

Sort By:
Pageof 7
Journal of Medicinal Chemistry|March 24, 2007
Pyrogallol-based molecules as potent inhibitors of the antiapoptotic Bcl-2 proteinsGuozhi Tang, Chao-Yie Yang, Zaneta Nikolovska-Coleska, et al.
Cancer Research|November 18, 2008
SM-164: a novel, bivalent Smac mimetic that induces apoptosis and tumor regression by concurrent removal of the blockade of cIAP-1/2 and XIAPJianfeng Lu, Longchuan Bai, Haiying Sun, et al.
Journal of the American Chemical Society|July 21, 2005
Structure-based design of potent non-peptide MDM2 inhibitorsKe Ding, Yipin Lu, Zaneta Nikolovska-Coleska, et al.
Molecular Cancer Therapeutics|June 21, 2008
Reactivation of p53 by a specific MDM2 antagonist (MI-43) leads to p21-mediated cell cycle arrest and selective cell death in colon cancerSanjeev Shangary, Ke Ding, Su Qiu, et al.
Journal of the American Chemical Society|November 15, 2007
Design, synthesis, and characterization of a potent, nonpeptide, cell-permeable, bivalent Smac mimetic that concurrently targets both the BIR2 and BIR3 domains in XIAPHaiying Sun, Zaneta Nikolovska-Coleska, Jianfeng Lu, et al.
Molecular Cancer Therapeutics|March 5, 2011
Therapeutic potential and molecular mechanism of a novel, potent, nonpeptide, Smac mimetic SM-164 in combination with TRAIL for cancer treatmentJianfeng Lu, Donna McEachern, Haiying Sun, et al.
Nature Immunology|June 11, 2003
An essential role for NOD1 in host recognition of bacterial peptidoglycan containing diaminopimelic acidMathias Chamaillard, Masahito Hashimoto, Yasuo Horie, et al.
Journal of Medicinal Chemistry|June 8, 2007
Structure-based design of flavonoid compounds as a new class of small-molecule inhibitors of the anti-apoptotic Bcl-2 proteinsGuozhi Tang, Ke Ding, Zaneta Nikolovska-Coleska, et al.
The Journal of Experimental Medicine|January 19, 2006
Nod1 acts as an intracellular receptor to stimulate chemokine production and neutrophil recruitment in vivoJunya Masumoto, Kangkang Yang, Sooryanarayana Varambally, et al.
Journal of Medicinal Chemistry|March 30, 2011
A potent and orally active antagonist (SM-406/AT-406) of multiple inhibitor of apoptosis proteins (IAPs) in clinical development for cancer treatmentQian Cai, Haiying Sun, Yuefeng Peng, et al.
Pageof 7